Amniocentesis

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Health, Genetics, Diagnosis, Incidence, Parent, Hospital, DSM-IV codes, Physician, Exome, Plasma, Research, SRL Diagnostics, Genome, Prevalence, PCR, BGI Group, NGS, DNA, CVS, Risk, SNV calling from NGS data, Sanger, Massive parallel sequencing, Metabolism, Amniocentesis, Genetic code, Disease, State Key Laboratories, R, Inherit, Genomics, Patient, Polymerase chain reaction, WES, WGS, Genetic counseling, Growth, Genetic testing, Region, National Centre for Foreign Animal Disease, Gene, Rare, Chromosome, Fetus, Cardiogenic shock, Serum, Birth, Gastroenterology, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023
Chromosome, DNA, Sanger, National Centre for Foreign Animal Disease, Gastroenterology, Prevalence, BGI Group, DSM-IV codes, Serum, Disease, Fetus, Genomics, Parent, Hospital, Cardiogenic shock, SRL Diagnostics, NGS, Amniocentesis, CVS, Genetic testing, Research, Birth, Genetic code, Exome, Incidence, Genetic counseling, Plasma, Metabolism, Patient, Polymerase chain reaction, Physician, Risk, State Key Laboratories, WGS, Inherit, Growth, Diagnosis, Region, R, Rare, WES, SNV calling from NGS data, Massive parallel sequencing, Gene, PCR, Genome, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Noninvasive Prenatal Testing: The Luna Prenatal Test for Isolation of Circulating Fetal Cells Early in Pregnancy, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 6, 2023
CVS, Walker–Warburg syndrome, Health, Blood, Cell, Pregnancy, Research, Fetus, Confined placental mosaicism, Luna, Trisomy, Amniocentesis, Risk, DSM-IV codes, Knowledge, R, Noninvasive prenatal testing, POMT1, Genetics, Dietary supplement, Genetic distance, Syndactyly-nystagmus syndrome due to 2q31.1 microduplication

TORONTO, March 6, 2023 /PRNewswire-PRWeb/ -- For decades, many groups around the world have pursued the isolation and genetic analysis of circulating fetal cells from maternal peripheral blood as an improved form of noninvasive prenatal testing. However, the exceeding rarity of these cells in the blood of pregnant women has proven a challenging obstacle in the establishment of a reliable test methodology.

Key Points: 
  • In this free webinar, learn about a breakthrough in the reliable isolation and successful analysis of circulating fetal cells for noninvasive prenatal testing early in pregnancy.
  • The featured speaker will discuss how the Luna Prenatal Test isolates and analyzes single circulating fetal cells early in pregnancy.
  • Attendees will learn how the Luna Prenatal Test makes a positive difference in patient care and reproductive health.
  • In collaboration with Juno Genetics, the Luna Prenatal Test isolated circulating fetal cells from a pregnancy at risk of Walker-Warburg Syndrome.

OGM Evaluated as a Method for Investigating Abnormal NIPT Results due to its Ability to Detect Chromosomal Structural Variations Found in Recurrent Pregnancy Loss

Retrieved on: 
Friday, October 14, 2022
Adoption, Non-functional testing, Genetic counseling, SAN, U.S. Securities and Exchange Commission, OGM, KT, Autism, Risk, Medicine, NIPT, Annual report, CMA, Patient, Lineagen, Biology, Hospital Insurance and Diagnostic Services Act, Research, Security (finance), Nasdaq, Private Securities Litigation Reform Act, Software, Amniocentesis, Company, Doctor of Philosophy, Karyotype, Chromosomal rearrangement, CCR, Genomics, Pregnancy loss, GLOBE, Infertility, Genome, Forward-looking statement, Chromosome, Pregnancy, COVID-19, Solution, Medical imaging

The study sought to determine OGMs utility for detection of chromosome breakages and fusions found in complex chromosomal rearrangements (CCR), which can significantly increase an abnormal pregnancy outcome for carrier couples.

Key Points: 
  • The study sought to determine OGMs utility for detection of chromosome breakages and fusions found in complex chromosomal rearrangements (CCR), which can significantly increase an abnormal pregnancy outcome for carrier couples.
  • The researchers used OGM as part of a confirmatory workflow after amniocentesis, karyotyping (KT), and chromosomal microarray analysis (CMA) identified suspected structural rearrangements with unknown origins, believed to indicate a CCR event.
  • We believe OGM could be used as a comprehensive follow-up genome analysis in cases with a positive NIPT screen or for some high-risk pregnancies.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Global Non Invasive Prenatal Testing Market Report (2022 to 2030) - Asia-Pacific is Expected to Exhibit the Highest CAGR Over the Forecast Period - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 6, 2022
Biotechnology, Genetics, Health, Adoption, Lists of diseases, Hospital, Risk, Technology, Government, Growth, Infection, NIPT, CAGR, List of mammalian gestation durations, Patient, Whole genome sequencing, Investment, Amniocentesis, Chromosome, Application, COVID-19, Down syndrome, Incidence, Down, DNA, Prenatal care, USD, Method, Health insurance, Pharmaceutical industry

The global non invasive prenatal testing market size is expected to reach USD 7.71 billion by 2030, according to this report., expanding at a CAGR of 9.61% from 2022 to 2030.

Key Points: 
  • The global non invasive prenatal testing market size is expected to reach USD 7.71 billion by 2030, according to this report., expanding at a CAGR of 9.61% from 2022 to 2030.
  • The increasing incidence of chromosomal abnormalities is expected to accelerate market growth.
  • Of all the countries, there is a substantial opportunity in China for non invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.
  • Cell-free DNA is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses
    Asia Pacific is expected to exhibit the highest CAGR over the forecast period.

DGAP-News: Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time

Retrieved on: 
Monday, July 25, 2022
Infection, University, III, Awareness, Woman, Observational study, Research, Immunoglobulin A, Institute, Safety, Fetus, Obstetrics, Immunoglobulin M, Immunoglobulin G, Pregnancy, Lists of diseases, Cytomegalovirus, CMV, Huber loss, Patient, National Institute of Virology, Amniocentesis, Child, Immunodeficiency with hyperimmunoglobulin M, Pharmaceutical industry, Birth control, Vaccine, Virology

Biotest is currently also conducting a phase III clinical trial with CMV hyperimmunoglobulin in pregnant women.

Key Points: 
  • Biotest is currently also conducting a phase III clinical trial with CMV hyperimmunoglobulin in pregnant women.
  • Dr.PhilippKolb from the Institute of Virology at the University of Freiburg is the first winner of the Renate&HansSchleussner Research Award.
  • The award supports a research project of the excellent winner in the field of cytomegalovirus (CMV) infection.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

Premier Medical Laboratory Services Now Offering Noninvasive Prenatal Testing

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Diabetes, Risk, DNA, NGS, Blood, Sex, COLA, Toxicology, Degenerative disease, Amniocentesis, CVS, Placenta, Edwards syndrome, Doctor of Philosophy, Multimedia, Patient, Woman, Down syndrome, Amniotic fluid, Insurance, Health, Edwards, Greenville Triumph SC, Method, Research, Whole genome sequencing, Industry, Aneuploidy, NIPT, Nucleic acid thermodynamics, 2020 Greenville Triumph SC season, Chromosome, Pregnancy, Chorionic villus sampling, CLIA, Trisomy, CEO, Medical imaging

GREENVILLE, S.C., May 18, 2022 /PRNewswire/ -- Premier Medical Laboratory Services (PMLS) is announcing today that they have added Noninvasive Prenatal Testing (NIPT) to their full line of medical diagnostic testing and risk screening services.

Key Points: 
  • GREENVILLE, S.C., May 18, 2022 /PRNewswire/ -- Premier Medical Laboratory Services (PMLS) is announcing today that they have added Noninvasive Prenatal Testing (NIPT) to their full line of medical diagnostic testing and risk screening services.
  • As a laboratory, PMLS strives to offer only the most advanced and accurate testing and screening available for optimal patient care.
  • Premier Medical Laboratory Services (PMLS), headquartered in Greenville, South Carolina, is the official health and wellness partner of the Greenville Triumph and an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA.
  • Their expansive menuof highly advanced tests and screenings include genomic risk assessment assays for various cancers, heart disease, and diabetes, as well as women's health panels, toxicology, allergy testing, pharmacogenomics, routine blood chemistry, and noninvasive prenatal testing (NIPT).

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

Retrieved on: 
Friday, January 7, 2022
Software, Research, Oncology, Consumer, Technology, Infectious Diseases, Genetics, Science, Baby, Maternity, Nanotechnology, Biotechnology, Health, Other Science, Knowledge, Blood, Severe acute respiratory syndrome coronavirus 2, QGEN, Fetus, Edwards syndrome, Growth, Research, Amniocentesis, PCR, PICO, NYSE, Proteomics, DNA, Life, U.S. Securities and Exchange Commission, Protein, Automation, Disorder, Disease, Trisomy, SEC, Down syndrome, Gene, Bacteria, Biomarker, Senior, Virus, Partnership, Molecular diagnostics, Patau syndrome, RNA, Genomics, Technology, Polymerase, Chromosome, Solution, QIAGEN, Budget, NIPT, Medical imaging, Vaccine, Fine chemical, Insight, Pharma, Academy

QIAGEN has entered into two new collaborations that extend the QIAcuity ecosystem:

Key Points: 
  • QIAGEN has entered into two new collaborations that extend the QIAcuity ecosystem:
    A collaboration with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGENs dPCR franchise.
  • QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system, said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN.
  • Our aim is to make digital PCR and QIAcuity the new standard in PCR.
  • We expect more than half of all traditional PCR applications to eventually move to digital PCR.

Bionano Genomics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Progress

Retrieved on: 
Thursday, November 4, 2021
The Journal of Molecular Diagnostics, Lymphatic system, Commercial, European Society for Medical Oncology, Amniocentesis, OGM, Genomics, Development, Leadership, FSHD, SAN, CVS, General manager, NASDAQ, Hospital, Doctor of Philosophy, NGS, Growth, Investment, Cytogenetics, Lloyds Bank Corporate Markets, European Society of Human Genetics, Lists of publishing companies, Software, Academic health science centre, Molecular diagnostics, Acquisition, GLOBE, Research and development, Company, Genome, Solution, Constitution, Facioscapulohumeral muscular dystrophy, Journal, Human genetics, BDA, Reproductive health, Shredding (disassembling genomic data), DNA, Patient, Total, Cryptocurrency, Management, Pharmaceutical industry, Medical imaging, Lithium

for microarray and next-generation sequencing (NGS), we are transitioning Bionano Genomics from being the structural variation company into a data solutions provider.

Key Points: 
  • for microarray and next-generation sequencing (NGS), we are transitioning Bionano Genomics from being the structural variation company into a data solutions provider.
  • Chris Stewart, Chief Financial Officer of Bionano added: Q3 was another excellent quarter.
  • Gross margin for the third quarter of 2021 was 24.8%, compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020.
  • The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.

BioFluidica™ Announces Promising New Data for Identifying Fetal Aneuploidy Using the LiquidScan™, a High Throughput Liquid Biopsy Platform.

Retrieved on: 
Friday, October 1, 2021
Blood, Biotechnology, Temperature, FISH, Amniocentesis, Gestational age, Diagnosis, Collection, CTC, NIPS, DNA, Patient, Trophoblast, Pregnancy, Anomaly, Biomarker, International Society, Aneuploidy, CEO, Chromosome, Disease management, Trisomy, SAN, Disease, Placenta, In situ hybridization, Technology, Non-functional testing, Prognosis, NIPT, Fluorescence, Fetus, Wright State University, CVS, Medical imaging

It shows that chromosome abnormalities (aneuploidy) can be identified in fetal cells isolated from maternal circulation during pregnancy using BioFluidica's high-throughput, high-sensitivity microfluidic system, the LiquidScan.

Key Points: 
  • It shows that chromosome abnormalities (aneuploidy) can be identified in fetal cells isolated from maternal circulation during pregnancy using BioFluidica's high-throughput, high-sensitivity microfluidic system, the LiquidScan.
  • "The data demonstrates the novel platform LiquidScancan capture and enrich circulating trophoblasts for diagnosing fetal chromosome abnormalities," said Rolf Muller, CEO of BioFluidica.
  • 1002/pd.6046), consisted of pregnant women known to have or strongly suspected of having a fetus affected by aneuploidy.
  • BioFluidica is revolutionizing disease detection by bringing better samples to millions of people.For more information please visit https://www.biofluidica.com/